Solvonis Therapeutics (LSE:SVNS) ROE % Adjusted to Book Value : -206.12% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Solvonis Therapeutics ROE % Adjusted to Book Value?

Solvonis Therapeutics's ROE % for the quarter that ended in Jun. 2024 was -68.02%. Solvonis Therapeutics's PB Ratio for the quarter that ended in Jun. 2024 was 0.33. Solvonis Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was -206.12%.

Solvonis Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Solvonis Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solvonis Therapeutics ROE % Adjusted to Book Value Chart

Solvonis Therapeutics Annual Data

Trend

May18

May19

May20

May21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-29.51

-316.10

Solvonis Therapeutics Semi-Annual Data
	May18	May19	May20	May21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial					-17.09	-23.59	-45.29	-484.10	-206.12

Competitive Comparison of Solvonis Therapeutics's ROE % Adjusted to Book Value

For the Specialty Industrial Machinery subindustry, Solvonis Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Solvonis Therapeutics's ROE % Adjusted to Book Value Distribution in the Industrial Products Industry

For the Industrial Products industry and Industrials sector, Solvonis Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Solvonis Therapeutics's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Solvonis Therapeutics ROE % Adjusted to Book Value Calculation

Solvonis Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-94.83%	/	0.30
	=	-316.10%

Solvonis Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-68.02%	/	0.33
	=	-206.12%

Solvonis Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Solvonis Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Solvonis Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

J4I:Germany

Address

Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF

Website

https://www.solvonis.com

Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.

Solvonis Therapeutics Headlines

No Headlines